All this appears to say is that they will be collecting data on PD-L1 upregulation. Max seemed to indicate that patients would be able to receive ICIs if PD-L1 was upregulated but in order for that to be an option I think they would need to amend the trial protocol. I don't think that would cause any problems if they were to amend it early, but I'll defer to those who know better on the board.